WINT stock gains 200 percent as Windtree Therapeutics trades near penny levels

Windtree Therapeutics (ISIN US97382D2049) WINT stock is quoted at 0.0003 dollars on the Nasdaq as of August 31, 2026, marking a 200 percent move in the latest market data after trading at 0.0001 dollars earlier that day according to MarketBeat.

Stock slides sharply year to date

For retail investors, the dramatic intraday percentage change in WINT stock stands in sharp contrast to its long term performance. MarketBeat data as of August 31, 2026 shows that Windtree Therapeutics shares started the year at 0.0320 dollars and have since fallen by 99.1 percent to 0.0003 dollars, underlining how far the company has slipped into penny stock territory in 2026.

The same MarketBeat overview indicates that WINT is listed on the Nasdaq exchange in the healthcare sector with a biotechnology industry classification, positioning the company among early stage drug developers that often rely on capital markets and partnerships to fund clinical programs.

Profitability metrics remain weak

Fundamental figures compiled by MarketBeat and based on Windtree Therapeutics filings show that the company reported trailing twelve month earnings per share of negative 8.77 dollars, highlighting a significant loss per share across the most recent twelve month period ended in late 2025 or early 2026.

MarketBeat also reports a net income of negative 1.79 million dollars for Windtree Therapeutics in its latest trailing twelve month period, implying that the company continues to operate at a loss while pursuing the development of new therapies. These profitability metrics, although modest in absolute terms, underline the financial challenge facing a small biotechnology issuer with only about 30 employees and limited scale.

Because Windtree Therapeutics is a loss making biotech without a positive price earnings ratio, valuation metrics such as the trailing price earnings multiple are listed as not applicable in the MarketBeat summary; investors instead tend to focus on cash runway, pipeline progress and potential partnership milestones when assessing such companies.

Cardiovascular and critical care pipeline

Windtree Therapeutics focuses on drug candidates for cardiovascular and critical care indications, building on its historical work in pulmonary medicine. According to the company profile summarised by MarketBeat, Windtree aims to develop therapies that address acute cardiovascular conditions where rapid intervention can improve patient outcomes, a niche that requires robust clinical evidence and often involves collaboration with hospital networks.

For retail investors considering WINT stock, the pipeline strategy means that future value creation depends less on current revenue and more on the successful progression of clinical trials, regulatory approvals and potential licensing deals. In this context, even modest changes in trial data or partnership news can have an outsized impact on a micro cap share trading at fractions of a dollar.

Share price context for WINT stock

With WINT stock at 0.0003 dollars on Nasdaq as of August 31, 2026 based on MarketBeat data, the current quotation sits far below the 0.0320 dollar level seen at the start of 2026. The 99.1 percent year to date drop underscores the risk profile of the share and highlights why many institutional investors may avoid exposure, leaving trading volumes largely in the hands of speculative retail traders.